Key Tronic Corporation announced it will release its first quarter fiscal 2027 financial results after market close on November 3, 2026. The company will hold a conference call at 2:00 PM Pacific Time to discuss these results, accessible online and by phone. This update is important for investors tracking Key Tronic's performance in the electronic manufacturing services sector. The company also provides design and manufacturing services globally, serving major original equipment manufacturers.
Key Tronic Corporation's upcoming first quarter fiscal 2027 results are noted here with Pluang's Industrials sector data as of Oct 24, 2026 01:11 WIB. Of 135 priced Industrials-sector US stocks tradable on Pluang, 54 rose and 80 fell today. Notable movers include American Airlines Group Inc (AAL) at USD 11.96 with a 1-day change of -5.08%, QXO Inc. Common Stock (QXO) at USD 10.47 down 4.99%, and Old Dominion Freight Line Inc (ODFL) at USD 182.53 down 3.88%, with ODFL showing 100% buy order activity on Pluang and a typical hold time of 77 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
